ClinicalTrials.gg
CompletedNCT03653260Updated Sep 24, 2019

A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children

A Phase 3 interventional study of Lidocaine (Zingo) and Placebo in Catheter Site Pain, Pain, Acute and Anesthesia, Local, sponsored by Lee's Pharmaceutical Limited. Completed at 1 site in China. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Lee's Pharmaceutical Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lidocaine in Acute Pain — 2 open to participants now, 3 under way, none of them phase 3. Lidocaine · Acute Pain.

Enrollment
3rd of 20
288 · median 66
Started
2018
with 2 others
Phase 3
2 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
1 of 20
Lee's Pharmaceutical Limited

Among the 20 studies testing lidocaine in Acute Pain, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 2 in phase 3, and was the 10th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

2 of the 20 studies testing lidocaine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lidocaine in Acute Pain, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of Zingo in treating pain associated with venipunture and peripheral venous cannulation.

03

Conditions studied

  • Catheter Site Pain
  • Pain, Acute
  • Anesthesia, Local

Browse trials for

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 3-12
  • About to undergo venipuncture or peripheral venous cannulation at the back of the hand or antecubital fossa
  • Have sufficient cognitive skills to identify faces depicting extremes of pain on the Wong-Baker FACES scale (age 3-12) and the extremes of pain on a 100 mm visual analog scale (VAS) (ages 8-12)
  • Signed , cooperative and agree to attend follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Any medical condition, non-compliance or instability (including but not limited to exceptionally upset, crying, anxiety) that in the judgement of the investigator might adversely affect the conduct of the study
  • Used any (including external or inhaled) sedatives, analgesics, anaesthetics or other agents/device that may affect the efficacy assessment
  • Subjects with tattoos, surgical scars, ports, implantable devices or a skin condition (e.g. excessive body hair) that may have interfered with the placement of Zingo or skin site assessments
  • Active local infection or other skin pathology at the site of venipuncture or peripheral venous cannulation.
  • Venipuncture of peripheral venous cannulation at the proposed site within the prior two weeks (longer if the wound is apparent)
  • Previous history of allergic reactions to any local anaesthetic or tape/adhesive dressing.
  • Participated in a clinical trial within three months prior to administration of study drug, or have already enrolled in a Zingo clinical trial before
  • At the discretion of the investigator, any subjects that may have to be withdrawn from the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    Lidocaine (Zingo)

    0.5mg lidocaine at 20 bar pressure

    Drug: Lidocaine (Zingo)

  • Placebo comparator
    Placebo

    no emitted particle at 20 bar pressure, identical in external appearance to Zingo

    Drug: Placebo

Interventions

  • 0.5 mg lidocaine, 20 bar pressure

    Also known as: Zingo

  • DrugPlacebo

    Placebo injector, 20 Bar pressure, empty injector

06

What researchers measure

Primary outcomes

  1. Wong-Baker FACES Pain Rating Scale After Venipuncture or Peripheral Cannulation

    Child's assessment of pain on venipuncture or peripheral venous cannulation (all ages) performed one to three minutes after Zingo/Placebo administration, measured using the Wong-Baker FACES pain rating scale. The scale includes pictures of facial expressions with correlating numerical scale of 0-10, 0 being no hurt and 10 being the worst hurt.

    Time frame: immediate after venipunture

Secondary outcomes

  1. 100-mm Visual Analogue Scale (VAS)

    Assessment of pain on venipuncture or peripheral venous cannulation by children age 8-12, measured using a 100-mm VAS (0-100) anchored at 0 for "no pain" and at 100 for "worst possible pain."

    Time frame: immediate after venipunture

  2. Response Rate

    Percentage of subject who score 0 or 1 in the FACES Pain Rating Scale

    Time frame: immediate after venipunture

  3. Compliance Score

    Compliance to venipuncture assess by investigator

    Time frame: immediate after venipunture

Other outcomes

  1. Adverse Event Frequency

    Time frame: 1 day

  2. Adverse Event Severity

    Time frame: 1 day

  3. Comfort of Zingo/Placebo Administration (Wong-Baker)

    Subject (all ages) to assess the level of comfort of Zingo/Placebo administration, measured using the Wong-Baker FACES scale (0-10), where 0 represent No Discomfort and 10 represent Worst Possible Discomfort.

    Time frame: immediate after venipunture

  4. Comfort of Zingo/Placebo Administration (VAS)

    Subject (age 8-12) to assess the level of comfort of Zingo/Placebo administration, measured using VAS pain rating scales (0-100), where 0 represent No Discomfort and 100 represent Worst Possible Discomfort.

    Time frame: immediate after venipunture

  5. Local Adverse Reaction

    Local Adverse Reactions including erythema, edema, pruritus and hemorrhage/petechiae by severity.

    Time frame: Pre-dose (0-1 hour before), immediately after dose, 15 minutes, 30 minutes

07

Study locations

1 site
  • Shanghai Children's Medical Center
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2019, 6 months.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Aug 31, 2018
StartActual
Aug 15, 2018
Primary completionActual
Feb 28, 2019
CompletionActual
May 21, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03653260
Collaborators
Zhaoke (Hefei) Pharmaceutical Limited
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Aug 15, 2018
Primary completion
Feb 28, 2019
Completion
May 21, 2019
Last update
Sep 24, 2019

Study contacts

Mazhong Zhang, MD
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion